Outsourcing Pharma presents its latest round-up of the movers and shakers within the pharmaceutical industry, including news from Icon, Cenduit and BIA.
Icon’s development solutions division has appointed Daniel Tang as general manager, Asia Pacific.
Previously the VP of operations and bioassay/DMPK at Frontage Laboratories, Tang will now lead the development of the Irish CRO’s (contract research organisation) early phase activities across the region, including bioanalytical laboratory services.
Mario Rocci, president of Icon development solutions, said: “We are very pleased to welcome Dr. Tang. His expertise, experience and leadership will be critical as we expand our presence and range of services in the Asia Pacific region to support the growing clinical trials market there.”
Interactive response technologies (IRT) services provider Cenduit has named Andrew Roth and Kirsten Ferrandiz as new members of its management team.
Roth, the firm’s new global head of technology, joins Cenduit from Tekelec, where he served as director of engineering services.
Former senior director of product management and strategy at Oracle, Ferrandiz, will become senior director of account management.
“As a specialist in randomization and clinical trial supply management, Cenduit is in a strong position to lead the way as clinical trials become more global and complex,” said Roth.
Ferrandiz added: “I’m excited to contribute to Cenduit’s success in the increasingly dynamic IRT space.”
The BioIndustry Association (BIA) has drafted in Glyn Edwards as its interim chief executive following the immediate departure of Nigel Gaymond.
Edwards has been CEO of Antisoma for the past 12 years.
He said: “I am looking forward to working with BIA members, its Board and staff to help ensure that the UK's life sciences sector is recognised not only here in the UK but also globally.”
Of Gaymond’s departure, chairman of the trade association – whose members include service providers to the bioscience sector as well as pharmaceutical companies – Tim Edwards said: “I am delighted that Glyn has been able to join the BIA at this time. Nigel Gaymond has left to pursue other opportunities and I thank him for his engagement with members and his contribution to the BIA over the past two years.”
Kevin Hickey has joined the board of directors at clinical decision support firm DiagnosisOne.
In his new role, Hickey will provide strategic guidance on the growth, development and future direction of the company.
Hickey is also the is the principal, founder and director of HES Advisors, a strategic advisory firm serving the healthcare, health information technology and life sciences industries.
“DiagnosisOne is delivering the next generation of clinical decision support tools and analytics solutions to help care payers and providers continuously improve care quality,” said Hickey.
“I look forward to helping the company meet the growing demand for its cutting edge technology that enables healthcare organizations to improve outcomes, satisfy regulatory requirements and reduce costs.”
Healogix has announced founder Tim Edbrooke’s appointment as president and chief operating officer.
Edbrooke – who joined Healogix in 2009 as chief business officer – said of his new role: “Our clients are facing one of the most challenging times in our industry's history: access to physicians is getting even more difficult, payers' influence is increasing, and the complexity of variables that impact prescribing is only compounding.
“I'm looking forward to continuing to work with the great team we've assembled to lead us into another year of growth and advancement.”
Prior to Healogix, he was chief executive officer of Genactis.